Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol (LDL-c) levels.
• This leads to premature atherosclerosis and increased risk of cardiovascular events.
• Current treatments like statins, ezetimibe, and bile acid sequestrants are effective but often insufficient to reach LDL-c goals.

Purpose of the Study:

• To review recent clinical trials of novel drug classes for FH management.
• To assess the potential of these new therapies to improve LDL-c control and patient outcomes.
• To discuss the efficacy and safety profiles of emerging FH treatments.

Main Methods:

• Review of recent clinical trials for MTP inhibitors, apolipoprotein B synthesis inhibitors (e.g., mipomersen), CETP inhibitors, and PCSK9 inhibitors.
• Analysis of reported effects on lipid profiles.
• Evaluation of identified side-effects and limitations in drug development.

Main Results:

• Several new drug classes, including MTP inhibitors, mipomersen, CETP inhibitors, and PCSK9 inhibitors, demonstrate potential in lowering LDL-c.
• These agents show promise in improving lipid profiles for FH patients.
• The development of certain agents has been limited by identified side-effects.

Conclusions:

• Emerging drug classes offer new avenues for managing familial hypercholesterolemia.
• Long-term effects, including clinical outcomes and safety, require further investigation.
• These novel therapies have the potential to significantly impact future FH treatment strategies.